Ambrx, Inc.

Amha Hewet

Jason Pinkstaff

Nick Knudsen

Vadim Kraynov

Lorraine Sullivan

Kristine De Dios

Ying Sun

Richard Spence Barnett

Sandra Biroc

Timothy Buss

Damien Bresson

Tsotne Javahishvili

Shailaja Srinagesh

Nickolas Knudsen

Jason K Pinkstaff

Vadim Karynov

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Anti-CD70 antibody drug conjugates

Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.

Modified relaxin polypeptides and their uses

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are &#x3b1;CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the &#x3b1;CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Modified relaxin polypeptides and their uses thereof are provided.

Nucleic acids encoding modified relaxin polypeptides

Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides

Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid

Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain

Therapeutic uses of modified relaxin polypeptides for the treatment of cardiovascular disease, treatment of heart failure, and decreasing fibrotic disorders are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.

Therapeutic uses of modified relaxin polypeptides

Method of treating heart failure with modified relaxin polypeptides

Modified relaxin polypeptides and their uses, including therapeutic uses thereof for the treatment of a fibrotic disorder or heart failure are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.

Growing community of inventors

Chula Vista, CA, United States of America

Amha Hewet